Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States
Ana CorrioneroiD, Niall PrendivilleiD, Tatiana Cazorla, María Baena-NuevoiD, Sandra RöhmiD, Emilio CamafeitaiD, Stefan KnappiD, Patricia Alfonso
Abstract
In cancer therapy, traditional approaches often overlook the dynamic nature of drug-target interactions. We introduce kinetic fingerprints as a mechanistically informative tool to guide kinase inhibitor design and predict clinical performance. Profiling 172 compounds across multiple KIT conformations, including the oncogenic D816V mutation, show that prolonged residence time determines therapeutic success, while mutations accelerating dissociation rates (koff) drive resistance, positioning koff as a robust predictor of clinical failure. Beyond efficacy and resistance, kinetic signatures map molecular behavior: fast-associating scaffolds engage readily populated KIT states, slow binders overcome conformational barriers like juxtamembrane repositioning, and extended residence times highlight ligands stabilizing regulatory elements (G-loop and regulatory spine). Kinetic profiling further unveils mechanisms invisible to conventional methods, such as drug-induced kinase degradation, and exposes selectivity dimensions beyond affinity: avapritinib exhibits durable KIT D816V engagement yet transient off-target binding. Our findings redefine the evaluation of KIT inhibitors, establishing a framework for rational, kinetics-guided drug discovery in KIT-driven cancers. Table of Contents O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=166 SRC="FIGDIR/small/726488v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@17f522borg.highwire.dtl.DTLVardef@1ebabc6org.highwire.dtl.DTLVardef@15a5e61org.highwire.dtl.DTLVardef@1ea5e0e_HPS_FORMAT_FIGEXP M_FIG Kinetic profiling of 172 compounds across KIT conformationsincluding D816Vreveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug design in KIT-driven cancers. C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 2.65
- Field percentile
- top 10%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Revealing acquired resistance mechanisms of kinase-targeted drugs using an on-the-fly, function-site interaction fingerprint approach
Z. Zhao, P. E. Bourne·bioRxiv·Nov 13, 2019
- Dynamics of human protein kinases linked to drug selectivity
D. Kern, W. Pitsawong, … X. Meniche·bioRxiv·Mar 21, 2018
- MAPK Pathway Inhibition Reshapes Kinase Chemical Probe Reactivity Reflecting Cellular Activation States
Andrew F. Jarvis, Mohd Younis Bhat, … Donita C. Brady·ACS Bio & Med Chem AuPeer-reviewed·Jan 23, 2026
- Profiling of the drug resistance of thousands of Src tyrosine kinase mutants uncovers a regulatory network that couples autoinhibition to catalytic domain dynamics
S. Chakraborty, E. Ahler, … D. J. Maly·bioRxiv·Dec 5, 2021
- Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding
Sukrit Singh, Vytautas Gapsys, … John D. Chodera·The Journal of Physical Chemistry BPeer-reviewed·Mar 7, 2025
- Kinases in motion: impact of protein and small molecule interactions on kinase conformations
V. Kugler, S. Schwaighofer, … E. Stefan·bioRxiv·Jan 11, 2024